US Stock Insider Trading | Palvella disclosed 4 insider transactions on February 20

2026-02-20 22:20:20

On February 20, 2026, Palvella (PVLA) disclosed four insider trading transactions. Executive Goin Kathleen sold 3,026 shares on February 18, 2026.

[Recent Insider Transactions]

Disclosure Date	Position	Name	Transaction Date	Buy/Sell	Quantity	Price per Share/USD	Total Amount/USD
February 20, 2026	Executive	Goin Kathleen	February 18, 2026	Sell	1,276	79.97	102,000
February 20, 2026	Executive	Goin Kathleen	February 18, 2026	Buy	2,154	7.14	15,400
February 20, 2026	Executive	Goin Kathleen	February 18, 2026	Sell	3,026	79.16	239,500
February 20, 2026	Executive	Goin Kathleen	February 18, 2026	Buy	2,148	9.08	19,500
January 23, 2026	Executive	Goin Kathleen	January 21, 2026	Sell	3,749	97.94	367,200
January 23, 2026	Executive	Goin Kathleen	January 21, 2026	Buy	2,148	9.08	19,500
January 23, 2026	Executive	Goin Kathleen	January 21, 2026	Sell	553	95.49	52,800
January 23, 2026	Executive	Goin Kathleen	January 21, 2026	Buy	2,154	7.14	15,400
December 19, 2025	Executive	Goin Kathleen	December 17, 2025	Buy	2,154	7.14	15,400
December 19, 2025	Executive	Goin Kathleen	December 17, 2025	Sell	4,302	96.47	415,000

[Company Information]

Palvella Therapeutics, Inc. was incorporated under Nevada law on May 24, 2013. The company is a biotechnology firm that has historically discovered and developed drugs based on Anticalin proteins, targeting validated disease pathways in a unique and transformative manner. On March 27, 2024, the company implemented measures to maximize its ability to collect potential milestones from its collaborative clinical pipeline of drug candidates and to maintain the ability to consider other strategic options. The company’s clinical pipeline includes immuno-oncology or IO bispecific drugs developed in collaboration with partners, including S095012 (also known as PRS-344), targeting PD-L1 and 4-1BB; SGN-BB228 (also known as PRS-346), targeting CD228 and 4-1BB; and BOS-342 (also known as PRS-342), targeting GPC3 and 4-1BB. Anticalin proteins are proprietary to the company, representing a new class of therapeutics that have been validated clinically through collaborations with leading pharmaceutical companies.

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.

1 Likes